Core Insights - The company, Gilead Sciences, has announced promising preclinical efficacy results for its obesity treatment candidates ASC47 and ASC31, which are a combination of a dual receptor agonist and a selective small molecule agonist [1][2] Group 1: Drug Development - ASC31 is a novel GLP-1R and GIPR dual receptor agonist peptide developed by the company, showing favorable pharmacokinetic characteristics in non-human primates and positive in vivo efficacy in DIO mice [1] - ASC47 is a selective small molecule agonist of thyroid hormone receptor β (THRβ) that targets fat and is designed for monthly subcutaneous injection, achieving high drug concentrations in adipose tissue [1] Group 2: Market Potential - The combination of ASC31 and ASC47 demonstrates superior weight loss effects in animal models compared to existing weight loss drugs and other candidates in development, indicating significant differentiation potential in the obesity treatment market [2] - The company is building a robust pipeline of potential obesity therapies that includes both small molecules and peptides, with expectations for future progress updates [2]
歌礼制药-B(01672.HK)：ASC47与GLP-1R/GIPR双受体激动剂多肽ASC31联用在肥胖动物模型中显示出优于ASC47与替尔泊肽联用的减重效果